玛莱克琳生物技术公司Moleculin Biotech, Inc. （MBRX） 2017年10-K年度报告「NASDAQ」.pdf

1、2017 Annual ReportWe are highly focused on developing treatments for rare and di?cult cancers such as acute myeloid leukemia(“AML”);glioblastoma;cutaneous T-cell lymphoma,(“CTCL”),a deadly form of skin cancer;and pancreatic cancer.Critical to this e?ort is leveraging our continued collaborations and

2、 relationships with world-leading cancer centers like MD Anderson Cancer Center,Emory University,the Mayo Clinic and others.We have three highly di?erentiated technologies(focused on DNA targeting,cell signaling and tumor metabolism)that we believe have breakthrough potential to treat these di?cult

3、cancers.From those three core technologies,we now have six potential oncology drug candidates.One of those drugs is currently in clinical trials,and we expect two more to begin clinical trials this year.The achievements of 2017 are the foundation from which we will build this company going forward.W

4、e now have a diverse oncology drug development portfolio that gives Moleculin multiple shots on goal.DEAR SHAREHOLDERS2017 was a great year for Moleculin.We made signi?cant progress in advancing from a preclinical company at the beginning of the year to a clinical stage company developing oncology d

5、rug candidates that could be“game changers”for cancer patients by the end of the year.DEVELOPMENT PIPELINEOur potentially disruptive technologies include Annamycin,a DNA targeting chemotherapy agent that is active against multidrug resistant tumor cells and has been designed to be non-cardio toxic(u

6、nlike currently approved drugs in this class);immuno-stimulating STAT3 inhibitors WP1066 and WP1732 that target the cell signaling of glioblastoma,pancreatic cancer and many other tumors;and WP1122,an inhibitor of glycolysis that has been shown in preclinical testing to e?ectively disrupt the metabo